MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/87.5/0.1/20.12.24 | Real-time Bid/Ask 10:46:21 03/06/2024 pm IST | ||
| 0.26 EUR / 0.27 EUR | +19.37% |
|
| 1 month | +20.00% | ||
| 3 months | +362.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 0.26 | +17.12% |
| 31/24/31 | 0.222 | +15.62% |
| 30/24/30 | 0.192 | +3.78% |
| 29/24/29 | 0.185 | -3.14% |
| 28/24/28 | 0.191 | -13.18% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 09:54 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB3KH2 |
| ISIN | DE000MB3KH20 |
| Date issued | 10/02/2023 |
| Strike | 87.5 $ |
| Maturity | 20/12/2024 (200 Days) |
| Parity | 10 : 1 |
| Emission price | 0.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.58 € |
|---|---|
| Lowest since issue | 0.015 € |
| Spread | 0.01 € |
| Spread % | 3.85% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Warrants
- Warrant
